New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:08 EDTPSDV, ALIMpSivida announces resubmission of NDA for ILUVIEN
pSivida Corp. (PSDV) announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration. In the resubmission, pSividas licensee, Alimera Sciences (ALIM), responded to questions raised in the FDAs October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe. Alimera is awaiting the FDAs acceptance of the resubmission and a Prescription Drug User Fee Act date. pSivida will report that information when it becomes available.
News For PSDV;ALIM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
07:33 EDTPSDVpSivida receives $25M milestone payment
pSivida announced that it has received the $25M milestone payment under its out-license of ILUVIEN for the treatment of diabetic macular edema. The milestone was earned on the approval of ILUVIEN by the U.S. Food and Drug Administration. This milestone payment together with our cash on hand should fund our planned product development and other operations into calendar 2017. In addition, we will receive 20% of any net profits from sales of ILUVIEN for DME on a country-by-country basis as well as royalties on sales of Retisert, said Dr. Paul Ashton, Ph.D., President and CEO of pSivida Corp.
October 23, 2014
10:42 EDTALIMHigh option volume stocks
High option volume stocks: ALIM ROC CAKE MDXG SMH CFX CRI INFN LTM

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use